Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 118460


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 118460

License Grant
The Company has the exclusive right to promote and sell AmBisome in all countries, except the United States and Canada.  The Licensor has the exclusive right to promote and sell AmBisome in Canada.  In the United States the Company will have the right to co-promote AmBisome with Licensor and Licensor will have the primary responsibility for promoting and selling AmBisome in the United States.
License Property
AmBisome-Registered Trademark- A drug for treating and preventing life-threatening fungal infections.

AmBisome is a liposomal formulation of amphotericin B. Amphotericin B is a powerful antifungal agent that is well known for its ability to attack and kill a broad variety of life-threatening fungal infections but also has serious side effects, including kidney toxicity.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 1645

License Grant
An agreement for the sales of AmBisome in significant Asian markets, including Japan.
License Property
AmBisome is a liposomal formulation of amphotericin B, a well-established antifungal agent that is effective against a broad spectrum of fungi – clinical trial.

The Company co-developed and co-promotes AmBisome in the United States.

IPSCIO Record ID: 27375

License Grant
The Company has licensed certain technology from the University.
License Property
AmBisome is an antifungal agent; use as a primary therapy for patients with a low white blood cell count (febrile neutropenia) who have a presumed fungal infection, also known as fever of unknown origin or FUO, or with visceral leishmaniasis and as a secondary treatment for fungal infections that do not respond to amphotericin B treatment.
Field of Use
The Field of Use apply to the healthcare industry.

IPSCIO Record ID: 2734

License Grant
Our rights to market AmBisome are subject to a 1991 agreement between the two companies. Under the terms of the agreement, as amended, the companies co-promote AmBisome in the U.S., one company has sole marketing rights to AmBisome in Canada and the other company has exclusive marketing rights to AmBisome in the rest of the world, provided we pay royalties in connection with sales in most significant Asian markets, including Japan.

IPSCIO Record ID: 310523

License Grant
The Parties previously entered an agreement regarding research and development of certain liposomal, or lipid-based, formulations of amphotericin B.  

Amphotericin B is used for the treatment of fungal infections.

The Parties now intend to transfer the technology in the possession of Licensor relating to the manufacture of ABLC®.

By this agreement, Licensor grants an exclusive license to employ Technology for any purpose in the Field and a non-exclusive license for any purpose outside the Field.

Licensor transfers all rights to use ABLC® trademark in connection with the COMPLEX and reserves no rights for itself.

License Property
Licensor is engaged in the development, manufacture and sale of pharmaceutical products.

Technology shall mean information relating to COMPLEX which is in the possession of B-MS on December 31, 1992 and patent applications U.S. Serial Nos. 07/876,121 and 08/052,815.

COMPLEX shall mean a liposomal, or lipid-based, formulation of amphotericin B that was under joint development by the parties pursuant to the 1986 Agreement.

Field of Use
Amphotericin B is used for the treatment of fungal infections.  Field shall mean manufacture, sale, shipment, storage or use of the COMPLEX.

Licensee is engaged in the development, manufacture and sale of liposome-and other lipid-based, pharmaceutical products and has developed a lipid-based formulation of the antifungal agent amphotericin B, this agent-lipid complex being generally known as ABLC®.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.